While at Pacific Biosciences, Michael Hunkapiller saw significant fluctuations in his stock holdings alongside the company’s stock value. Notably, in 2019, his holdings peaked with insider trades valued at $12.22M, showing strong interest in the company’s performance. This trend continued...

While at Pacific Biosciences, Michael Hunkapiller saw significant fluctuations in his stock holdings alongside the company’s stock value. Notably, in 2019, his holdings peaked with insider trades valued at $12.22M, showing strong interest in the company’s performance. This trend continued into 2020, where he recorded some of his highest trades at $44.48M by October, reflecting the positive growth trajectory at that time. However, as the market shifted, his trades decreased significantly in the following years, illustrating the volatile nature of the biotech sector and Hunkapiller’s strategic decisions to manage risk amidst changing valuations. His holdings tell a story of a leader who was deeply intertwined with the success of Pacific Biosciences throughout his tenure.